Aridis Pharmaceuticals Analyst Ratings
Aridis Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/20/2023 | 3821.57% | HC Wainwright & Co. | $10 → $2 | Maintains | Buy |
| 01/26/2023 | 19507.84% | HC Wainwright & Co. | $19 → $10 | Maintains | Buy |
| 08/16/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/20/2021 | 37154.9% | HC Wainwright & Co. | $11 → $19 | Maintains | Buy |
| 05/15/2020 | 21468.63% | HC Wainwright & Co. | $7 → $11 | Reiterates | → Buy |
| 02/19/2020 | 35194.12% | Roth Capital | → $18 | Initiates Coverage On | → Buy |
| 12/30/2019 | 13625.49% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 10/20/2023 | 3821.57% | HC Wainwright公司 | $10→$2 | 維護 | 買 |
| 2023年1月26日 | 19507.84% | HC Wainwright公司 | $19→$10 | 維護 | 買 |
| 08/16/2022 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 07/20/2021 | 37154.9% | HC Wainwright公司 | $11→$19 | 維護 | 買 |
| 2020/05/15 | 21468.63% | HC Wainwright公司 | $7→$11 | 重申 | →購買 |
| 02/19/2020 | 35194.12% | 羅斯資本 | →$18 | 開始承保 | →購買 |
| 2019年12月30日 | 13625.49% | HC Wainwright公司 | →$7 | 開始承保 | →購買 |
What is the target price for Aridis Pharmaceuticals (ARDS)?
阿裡迪斯製藥公司(ARDS)的目標價是多少？
The latest price target for Aridis Pharmaceuticals (OTCQB: ARDS) was reported by HC Wainwright & Co. on October 20, 2023. The analyst firm set a price target for $2.00 expecting ARDS to rise to within 12 months (a possible 3821.57% upside). 2 analyst firms have reported ratings in the last year.
2023年10月20日，HC Wainwright&Co.報道了阿裡迪斯製藥公司(OTCQB：ARDS)的最新目標價。這家分析公司將目標價定為2美元，預計ARDS將在12個月內升至(可能上漲3821.57%)。去年有兩家分析公司公佈了評級。
What is the most recent analyst rating for Aridis Pharmaceuticals (ARDS)?
分析師對阿裡迪斯製藥(ARDS)的最新評級是多少？
The latest analyst rating for Aridis Pharmaceuticals (OTCQB: ARDS) was provided by HC Wainwright & Co., and Aridis Pharmaceuticals maintained their buy rating.
分析師對阿裡迪斯製藥公司(場外交易代碼：ARDS)的最新評級是由HC Wainwright&Co.提供的，阿裡迪斯製藥公司維持其買入評級。
When is the next analyst rating going to be posted or updated for Aridis Pharmaceuticals (ARDS)?
阿裡迪斯製藥公司(ARDS)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Aridis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Aridis Pharmaceuticals was filed on October 20, 2023 so you should expect the next rating to be made available sometime around October 20, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與阿裡迪斯製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。阿裡迪斯製藥的上一次評級是在2023年10月20日提交的，所以你應該預計下一次評級將在2024年10月20日左右的某個時候公佈。
Is the Analyst Rating Aridis Pharmaceuticals (ARDS) correct?
分析師對阿裡迪斯製藥公司(ARDS)的評級正確嗎？
While ratings are subjective and will change, the latest Aridis Pharmaceuticals (ARDS) rating was a maintained with a price target of $10.00 to $2.00. The current price Aridis Pharmaceuticals (ARDS) is trading at is $0.05, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的阿裡迪斯製藥(ARDS)評級維持不變，目標價在10.00美元至2.00美元之間。阿裡迪斯製藥(ARDS)目前的交易價格為0.05美元，超出了分析師的預測區間。